Differential reduction in the volume of leiomyoma and uterus during buserelin treatment

References

• Feroze R. M. Benign tumors of the uterus. Integrated Obstetrics and Gynecology for Postgraduates, 3rd edn., J. Dewhurst. Blackwell Scientific, Oxford 1981; 696–703
   Google Scholar
• Fraser H. M., Baird D. T. Clinical application of LHRH analogues. Baillière's Clin. Endocrinol. Metab. 1987; 1: 43–7
   PubMedGoogle Scholar
• Miller N. F., Ludovici P. P. Origin and development of uterine fibroids. Am. J. Obstet. Gynecol. 1955; 70: 720–6
   Google Scholar
• Filicori M., Hall D. A., Loughlin J. S., Rivier J., Vale W. A conservative approach to the management of uterine leiomyoma: pituitary desensitisation by an LHRH analogue. Am. J. Obstet. Gynecol. 1983; 147: 726–7
   PubMed Web of Science ®Google Scholar
• Healy D., Fraser H., Lawson S. Shrinkage of a uterine fibroid after subcutaneous infusion of a LHRH agonist. Br. Med. J. 1984; 289: 1267–8
   PubMedGoogle Scholar
• Coddington C. C., Collins R. L., Shawker T. H., Anderson R., Loriaux D. L., Winkel C. A. Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri. Fertil. Steril. 1986; 45: 624–9
   PubMed Web of Science ®Google Scholar
• West C. P., Lumsden M. A., Lawson S., Williamson J., Baird D. T. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as monthly subcutaneous depot. Fertil. Steril. 1987; 48: 45–51
   PubMed Web of Science ®Google Scholar
• Perl V., Marquez J., Schally A. V., Comaru-Schally A. M., Leal G., Zacharias S., Gomez-Lira C. Treatment of leiomyomata uteri with D-Trp6-luteinizing hormone-releasing hormone. Fertil. Steril. 1987; 48: 383–9
   PubMedGoogle Scholar
• Maheux K., Lemay A., Turcot-Lemay L. Dose-related inhibition of acute luteinizing hormone-releasing hormone agonist treatment for uterine leiomyomas. Am. J. Obstet. Gynecol. 1988; 158: 361–4
   Google Scholar
• Nakaniura Y., Yoshimura Y., Yamada H., Ubukata Y., Ando M., Suzuki M. Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women. Fertil. Steril. 1991; 55: 900–5
   Google Scholar
• Matta W. H. M., Stabile I., Shaw R. W., Campbell S. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist buserelin. Fertil. Steril. 1988; 49: 1083–5
   PubMed Web of Science ®Google Scholar
• Healy D. L. The use of LHRH analogues in the treatment of uterine fibroids. Gynecol. Endocrinol. 1989; 3(suppl. 2)33–49
   Google Scholar
• Rolland R., Frassen A. M. H.W., Willemsen W. N. P., Corbey R. S. Uterine leiomyoma and agonist treatment: a preliminary report. Gonadotrophin Down Regulation in Gynecological Practice, R. Rolland, et al. Alan R. Liss Inc., New York 1986; 313–20
   Google Scholar
• Friedman A. J., Harrison-Atlas D., Barbieri R. L., Benacerraf B., Gleason R., Schiff I. A randomized placebo-controlled double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata. Fertil. Steril. 1989; 51: 251–6
   PubMed Web of Science ®Google Scholar
• Friedman A. J., Barbieri R. L., Benacerraf B., Schiff I. Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist. Fertil. Steril. 1987; 48: 560–4
   PubMed Web of Science ®Google Scholar
• Andreyko J. L., Blumenfeld Z., Marshall L. A., Monroe S. E., Hricak H., Jaffe R. B. Use of an agonistic analog of gonadotrophin-releasing hormone (nafarelin) to treat leiomyomas: assessment by magnetic resonance imaging. Am. J. Obstet. Gynecol. 1988; 158: 903–10
   Google Scholar
• Schlaff W. D., Zerhouni E. A., Huth J. A. M., Chen J., Damewood M. D., Rock J. A. A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (Leuprolide) in the treatment of uterine leiomyomata. Obstet. Gynecol. 1989; 74: 856–62
   PubMed Web of Science ®Google Scholar
• Upadhayaya N. B., Doody M. C., Googe P. B. Histopathological changes in leiomyomata treated with leuprolide acetate. Fertil. steril. 1990; 54: 811–14
   Google Scholar
• Wilson E. A., Yang F., Rees E. D. Estradiol and progesterone binding in uterine leiomyomata and normal uterine tissues. Obstet. Gynecol. 1980; 55: 2024–7
   Google Scholar
• Soules M. R., McCarty K. S. Leiomyomas: steriod receptor content. Am. J. Obstet. Gynecol. 1982; 143: 6–11
   PubMedGoogle Scholar
• Pollow K., Sinnecker G., Boguoi E., Pollow B. In vitro conversion of estradiol-17-beta into estrone in normal human myometrium and leiomyoma. J. Clin, Chem. Biochem. 1978; 16: 483–7
   Google Scholar